Amarantus Signs Non-Binding Term Sheet to Divest Cutanogen Corporation in Exchange for the Extinguishment of Potential $21M+ in Liabilities
- Board Member/Acting CEO Provides Shareholder Update - Sale of Engineered Skin Substitute (ESS) subsidiary, Cutanogen Corporation. - Emphasis placed on advancing Elto Pharma, Inc. and MANF Therapeutics...